Core B: System Biological Analyses of Innate and Adpative Responses to Vaccination
Core B: System Biological Analyses of Innate and Adpative Responses to Vaccination
批准号:
10201499
负责人:
Mark Joseph Mulligan
金额:
$512.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-13 至 2022-06-30
关键词:
2019-nCoVATAC-seqAddressAspirate substanceAwardBloodCOVID-19Cell Culture TechniquesCellsCloningCompetenceDiagnosticDiseaseDonor personEpigenetic ProcessEpithelial CellsEpitopesGenetic TranscriptionGrantHeterogeneityHospitalsHumanImmuneImmune responseImmune systemImmunityImmunologyInfectionInnate Immune ResponseKnowledgeLearningLungLung TransplantationMetabolicMolecularMolecular ProfilingMyelogenousMyeloid CellsNatural ImmunityParentsPathogenesisPathogenicityPeripheral Blood Mononuclear CellSamplingScienceSiteStimulusStructure of parenchyma of lungSystemSystems BiologyTherapeuticVaccinationVaccine DesignVaccinesVirusWorkairway epitheliumbiological systemscoronavirus diseasedesignepigenomicsglobal healthimprintindexinginsightmacrophagemetabolomicsmonocytemultiple omicsnovelpandemic diseasepreventprogramsresponsesingle-cell RNA sequencingtranscriptometranscriptomicstransplant centers
中文摘要
最近出现的新型致病性SARS冠状病毒2(SARS-CoV-2)大流行
对全球健康构成重大挑战。冠状病毒病(COVID-19)是由SARS引起的-
CoV-2是一种潜在致命疾病的病原体。科学已经非常
快速分离、测序和克隆病毒,并开发诊断试剂盒,
几周的事。然而,在以下方面仍然存在重大知识差距:
人类免疫系统和SARS-CoV-2。特别是,几个基本问题
关于其发病机制,以及需要诱导的保护性免疫机制,
接种疫苗,仍然没有答案。了解免疫系统如何感知SARS-CoV-2
感染和协调保护性免疫对于设计有效的疫苗至关重要,
治疗学我们以前的工作采用系统生物学、多组学的方法来分析
人类对疫苗接种的免疫应答已经描绘了先天免疫缺陷的分子特征,
免疫接种和感染,并提供了丰富的机制的见解,免疫
反应在本提案中,我们提出了一个特定地点的研究,以分析样本从
IMPACC子研究在Emory进行。我们将使用集成的多组学方法(单个
细胞转录组学、代谢组学、单细胞表观基因组学)来研究对COVID的先天免疫-
19人感染。我们将从IMPACC获得PBMC和气管抽吸物样本
将在埃默里进行的子研究。我们将讨论以下问题:
血液中对COVID-19感染的免疫反应的分子和细胞特征,
感染者的气管吸出物COVID-19感染是否会产生
先天免疫力?什么是髓系细胞亚群和气道的分子景观和功能
健康肺中的上皮细胞,以及COVID-19感染后?这些问题将
具体目标如下:1)确定单细胞转录和
血液和气管中对COVID-19感染的免疫反应的表观遗传景观
抽吸物,和2)确定骨髓细胞亚群的分子身份和功能,
人肺上皮细胞及其对COVID-19感染的反应。这些研究将提供
对人类对COVID-19感染的免疫反应的重要见解,
用于设计疫苗和治疗方法来预防或治疗感染。
英文摘要
The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) pandemic
poses a major global health challenge. Coronavirus disease (COVID-19) is caused by SARS-
CoV-2 and represents the causative agent of a potentially fatal disease. Science has moved very
rapidly in isolating, sequencing, and cloning the virus, and developing diagnostic kits, within a
matter of weeks. However, major knowledge gaps remain about the dynamic interaction between
the human immune system and the SARS-CoV-2. In particular, several fundamental questions
regarding its pathogenesis, and the mechanisms of protective immunity that need to be induced
by vaccination, remain unanswered. Learning how the immune system senses SARS-CoV-2
infection and orchestrates protective immunity is critical for designing effective vaccines and
therapeutics. Our previous work using systems biology, multi-omics approaches to analyze
immune responses to vaccination in humans has delineated molecular signatures of innate
immunity to vaccination and infection and have provided rich mechanistic insights into the immune
response. In this proposal, we propose a site-specific study to analyze samples from the
IMPACC sub-study performed at Emory. We will use an integrated multi-omics approach (single
cell transcriptomics, metabolomics, single cell epigenomics) to study innate immunity to COVID-
19 infection in humans. We will obtain PBMCs and tracheal aspirate samples from the IMPACC
sub-study that will be conducted at Emory. We will address the following questions: What are the
molecular and cellular signatures of the immune response to COVID-19 infection in the blood and
tracheal aspirates of infected subjects? Does COVID-19 infection exert an epigenetic imprint of
innate immunity? What is the molecular landscape and function of myeloid cell subsets and airway
epithelial cells in the healthy lung, and following COVID-19 infection? These questions will be
addressed in the following specific aims: 1) Determine the single cell transcriptional and
epigenetic landscape of the immune response to COVID-19 infection in blood and tracheal
aspirates, and 2) Determine the molecular identity and functions of myeloid cell subsets and
epithelial cells in human lung and their response to COVID-19 infection. These studies will provide
significant insight into the human immune response to COVID-19 infection that can be leveraged
for designing vaccines and therapeutics to prevent or treat the infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012
-
批准号:10411291
-
项目类别:
-
资助金额:$134.15万
-
财政年份:2021
-
负责人:Mark Joseph Mulligan
-
依托单位:
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) – DMID 21-0004
-
批准号:10416210
-
项目类别:
-
资助金额:$62.54万
-
财政年份:2021
-
负责人:Mark Joseph Mulligan
-
依托单位:
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
-
批准号:10493613
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2021
-
负责人:Mark Joseph Mulligan
-
依托单位:
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
-
批准号:10493604
-
项目类别:
-
资助金额:$54.37万
-
财政年份:2021
-
负责人:Mark Joseph Mulligan
-
依托单位:
Core B: System Biological Analyses of Innate and Adpative Responses to Vaccination
-
批准号:10345983
-
项目类别:
-
资助金额:$46.64万
-
财政年份:2021
-
负责人:Mark Joseph Mulligan
-
依托单位:
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
-
批准号:10265637
-
项目类别:
-
资助金额:$682.04万
-
财政年份:2021
-
负责人:Mark Joseph Mulligan
-
依托单位:
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
-
批准号:10228783
-
项目类别:
-
资助金额:$921.48万
-
财政年份:2020
-
负责人:Mark Joseph Mulligan
-
依托单位:
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
-
批准号:10534123
-
项目类别:
-
资助金额:$63.19万
-
财政年份:2020
-
负责人:Mark Joseph Mulligan
-
依托单位:
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
-
批准号:10306410
-
项目类别:
-
资助金额:$63.87万
-
财政年份:2020
-
负责人:Mark Joseph Mulligan
-
依托单位:
Vaccine and Treatment Evaluation Units: Overall Administration, Clinical Operations Support, Protocol Development, Implementation and Assays.
-
批准号:10083147
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2019
-
负责人:Mark Joseph Mulligan
-
依托单位:
Vaccine and Treatment Evaluation Units: Overall Administration, Clinical Operations Support, Protocol Development
-
批准号:10673575
-
项目类别:
-
资助金额:$10.65万
-
财政年份:2019
-
负责人:Mark Joseph Mulligan
-
依托单位:
Vaccine and Treatment Evaluation Units: Overall Administration, Clinical Operations Support, Protocol Development
-
批准号:10454731
-
项目类别:
-
资助金额:$10.63万
-
财政年份:2019
-
负责人:Mark Joseph Mulligan
-
依托单位:
Vaccine and Treatment Evaluation Units: Protocol Development and Implementation for a Natural History Challenge Study for Influenza
-
批准号:9934606
-
项目类别:
-
资助金额:$4.0万
-
财政年份:2019
-
负责人:Mark Joseph Mulligan
-
依托单位:
Vaccine and Treatment Evaluation Unit: Phase I Clinical Trial to Evaluate a Hepatitis E Vaccine
-
批准号:9915385
-
项目类别:
-
资助金额:$59.96万
-
财政年份:2018
-
负责人:Mark Joseph Mulligan
-
依托单位:
Vaccine and Treatment Evaluation Unit: Phase I Clinical Trial to Evaluate a Hepatitis E Vaccine
-
批准号:10453426
-
项目类别:
-
资助金额:$0.27万
-
财政年份:2018
-
负责人:Mark Joseph Mulligan
-
依托单位:
VTEU PHASE 2 EBOLA VIRUS VACCINE TRIAL
-
批准号:10001401
-
项目类别:
-
资助金额:$119.71万
-
财政年份:2018
-
负责人:Mark Joseph Mulligan
-
依托单位:
Vaccine and Treatment Evaluation Units: Protocol Development and Implementation for a Phase I Trial for Influenza Vaccine
-
批准号:9934625
-
项目类别:
-
资助金额:$58.89万
-
财政年份:2018
-
负责人:Mark Joseph Mulligan
-
依托单位:
Vaccine and Treatment Evaluation Unit - Clinical Operations Support
-
批准号:9737180
-
项目类别:
-
资助金额:$50.78万
-
财政年份:2018
-
负责人:Mark Joseph Mulligan
-
依托单位:
Vaccine and Treatment Evaluation Units: Protocol Development for a Phase III Dengue Vaccine Study
-
批准号:9915789
-
项目类别:
-
资助金额:$1.62万
-
财政年份:2017
-
负责人:Mark Joseph Mulligan
-
依托单位:
VACCINE TREATMENT AND EVALUATION UNIT: CLINICAL OPERATIONS SUPPORT
-
批准号:9571163
-
项目类别:
-
资助金额:$36.97万
-
财政年份:2017
-
负责人:Mark Joseph Mulligan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位: